Quantification of Dose with Neuromodulation Device

Marom Bikson
The City College of New York

Forum on Neuroscience and Nervous System Disorders: Multimodal Therapies for Brain Disorders. June 14-15, 2016






REVIEW ARTICLE

Fundamentals of transcranial electric and magnetic stimulation dose: Definition, selection, and reporting practices

Angel V. Peterchev, a, b Timothy A. Wagner, c, d Pedro C. Miranda, Michael A. Nitsche, Walter Paulus, Sarah H. Lisanby, Alvaro Pascual-Leone, Marom Bikson

Neuromodulation dose is "defined by all parameters of the stimulation device that affect the electric and current density fields generated in the body"


- 1)Stimulation electrode / coil configuration parameters: shape, size, position, and electrical properties
- 2)Electrode / coil current or voltage waveform parameters: pulse amplitude, width, polarity, repetition frequency, train duration, interval and number of stimulation sessions



wire

2) Electrodes outside or inside body, or coil outside body


Electrical current are generated inside the body leading to (govern) changes



Dose of neuromodulation devices

Only those parameters that influence currents in body








EM dose





Electrode/coil current/voltage waveform



Electrode/coil configuration

Subject





Choice of device type and settings

EM dose monitoring/ verification

Response measures: motor threshold, seizure threshold, cognitive, clinical response, side effects, etc.



Dosing decision

Reduced metrics (e.g., electrode current density, total charge, total energy)

Computational models

Subject data: age, sex, MRI, DTI, diagnosis



General knowledge (subject independent): mechanisms of action, prior clinical experience, etc.








Electrode/coil current/voltage waveform

Electrode/coil configuration/



Choice of device type and settings

FM dose mo, 'toring/ verific, tion motor reshed, seizure ti reshold, cogn ve, clinic respons, side effects, etc.



Dr ... rision


Red metrics (e.g., lectrode rrrent lensity, total charge, to lenergy)

Computational of dels


Surject data: age, sex MRI, DTI diagnasis

Not Dose

General knowledge (subject independing): mechanisms of action, prior conical experience, etc.




- Current generated in the body is NOT dose
- But critically defines outcomes of stimulation
- Current in body determined by dose and tissue properties
- And so is subject specific
- Can be predicted using models or measured (dosimetry)



Response measures: motor threshold, seizure threshold, cognitive, clinical response, side effects, etc.

- Response to stimulation is NOT dose
- But represent outcomes of stimulation
- Can be used to adjust dose
 (rTMS for Depression uses TMS MEP, closed-loop for epilepsy
 uses EEG, Seizure for ECT)
- Essentially all FDA cleared technologies measure responses to adjust stimulation* (biomarker, sensation, behavior..)
 *And studies / protocols do not report individual dose




- Device name (brand) is NOT dose
- Names end with "s" (Stimulation) that typically refer to how current is delivered to body and "intended" target.

"Transcranial", "deep", "nerve X"


Dose is controlled (prescribed)




Drug dose is set by systemic application (tablets...)




Pharmacologic activity (efficacy and safety) is determined by drug concentration at tissue



"Electroceutical" dose is set by stimulation parameters (coil/electrode and waveform)




"Electrical activity"
(efficacy and safety) is
determined by electric
fields at tissue



wire

2) Electrodes outside or inside body, or coil outside body

Electrical current are generated inside the body leading to (govern) changes



Dose of neuromodulation devices

Only those parameters that influence currents in body

Things other than DOSE matter

- Efficacy: Subject state (concurrent interventions).
 "Functional Targeting" vs. "Anatomical Targeting"
- Safety: Device physical features (electrode materials)



Journal of Neuroscience Methods 141 (2005) 171–198



www.elsevier.com/locate/ineumeth

Invited review

Electrical stimulation of excitable tissue: design of efficacious and safe protocols

Daniel R. Merrill^{a,*}, Marom Bikson^b, John G.R. Jefferys^c

 Department of Bioengineering, University of Utah, 20 South 2030 East, Biomedical Polymers Research Building, Room 108G, Salt Lake City, UT 84112-9458, USA
 Department of Biomedical Engineering, City College of New York, New York, NY, USA
 Division of Neuroscience (Neurophysiology), School of Medicine, The University of Birmingham, Birmingham B15 2TT, UK

Neuromodulation technologies with "Super-Synergy" such as transcranial Direct Current Stimulation*

- Mechanisms suggest limited functional outcomes when applied alone, but strong change in brain 'responsiveness'
- Boosts effects of concurrent therapy
- Also sensitive to other neuromodulators (drugs)

tDCS known to enhance ongoing neuro-plasticity

+

Behavioral / cognitive interventions produce lasting benefit through neuro-plasticity

- * As of 2016 the most studied neuromodulation technology
- * Not proprietary (owned by one company)
- * Safe enough to be widely used on healthy subjects

Recommendations

 Testing and application of neuromodulation devices should be driven by principle of REPRODUCABILITY.

When can dose be unreported / uncontrolled?

- •Use of biomarkers to adjust neuromodulation dose in a successful intervention should not be confused with verification the biomarker is useful. A name is not the same as verification of an anatomical target.
 - If assumptions are wrong, so are reasons to not report/control dose.
- •Create path to clinic (patients) for technologies that are not proprietary and not specific to one indication. Yet are very tolerated/safe and independently tested.

Quantification of Dose with Neuromodulation Device

Marom Bikson
The City College of New York

Forum on Neuroscience and Nervous System Disorders: Multimodal Therapies for Brain Disorders. June 14-15, 2016